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  SUMMARY 
 
CD44 is a cell-surface molecule that functions as a receptor for 
hyaluronan- a major component of the extracellular matrix. Its interaction 
with hyaluronan and structural diversity confers it a wide range of 
functions. CD44+ expression has been identified as a marker for a 
population of cells with cancer stem cell characteristics in head and neck 
squamous cell carcinoma (HNSCC). The aim of this study is to investigate 
the expression of CD44s in squamous cell carcinoma (SCC) of the oral 
tongue using immunohistochemistry, and to correlate CD44s expression 
with histopathological features and patient outcome. 
 
Immunohistochemical analysis of CD44s expression was performed on 
tongue SCC tissue obtained from 51 consecutive patients who underwent 
surgical resection between Jan 2002 to Oct 2005. CD44s expression was 
based on staining intensity and percentage of tumour cells expressing 
CD44s. Expression of CD44s and its association with histopathological 
parameters were analysed using either the Chi-square test or Fisher’s 
exact test as appropriate. The Kaplan Meier method was used to estimate 
survival distributions. Cox proportional hazard models were fitted to 
estimate hazard ratios to assess association of factors with each endpoint. 
 
The median follow-up since surgery was 4.2 years. Intensity of CD44s 
staining and percentage staining varied among the samples. Intensity of 
staining was found to be a better indicator of outcome. Patients with strong 
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CD44s staining intensity had better overall survival compared to patients 
with low or moderate CD44s intensity (HR 0.32, Log rank p = 0.04). Strong 
CD44s intensity was also associated with better locoregional recurrence-
free interval (HR 0.22, 95%CI 0.05 – 0.87; P = 0.029). There was no 
association between CD44s expression and adverse histopathological 
features. 
 
We conclude that strong staining intensity of CD44s is an independent 
positive prognostic factor for overall and locoregional recurrence-free 
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1.1 Head and Neck Cancers 
 
Squamous cell carcinomas of the head and neck (HNSCC) are epithelial 
malignancies that arise from the paranasal sinuses, oral cavity, 
oropharynx and larynx. As a group they represent the 6th most common 
type of cancer in Western countries, accounting for an estimated 650 000 
new cancer cases and 350 000 cancer deaths worldwide every year.1 Oral 
cancer alone accounts for 270 000 new cases annually and 145 500 
annually, the majority of which occur in developing countries.1 These 
cancers are largely amendable to curative surgery or radiotherapy, with or 








1.2.1 Epidemiology and Etiology 
 
  
Tongue cancer is the most common malignancy arising from the oral 
cavity in the head and neck. As with most cancers in the head and neck, 
squamous cell carcinoma (SCC) is the most common.2 Worldwide, oral 
tongue SCC is an important cause of morbidity and mortality, although a 
significant geographical variation exists. Once considered to be a cancer 
on the decline in the developed world, a rising incidence suggests a 
continuing increase in the absolute numbers of cases to be treated in the 
coming decades.3 In India, incidence rates among males of up to 6.5 per 
100 000 per year have been reported.  In parts of Europe, like France, the 
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male incidence rate is 8.0 per 100 000 per annum.4 Based on the National 
Cancer Institute’s (NCI) Surveillance Epidemiology and End Results 
(SEER) cancer statistics, within the United States, an estimated 12,770 
new diagnoses of oral tongue SCC will made and an estimated 2050 men 
and women will die of oral tongue cancer in 2012.5 
 
The etiology of tongue SCC is well described. Tobacco use, heavy alcohol 
consumption, poor nutrition, immunocompromised health states and viral 
infections have all been implicated in the carcinogenesis of squamous cell 
carcinoma of the tongue. Of these risk factors, tobacco and alcohol 




1.2.2 Current opinions in management and therapy 
 
The oral tongue is defined as the anterior two-thirds of the tongue that lies 
within the oral cavity. Tumours that arise from the posterior one-third, or 
base of tongue, are defined as oropharyngeal cancers. Patients with oral 
tongue SCC usually present earlier than those with tumours at the base of 
tongue, largely due to better visibility to both patient and clinician. Despite 
this, many patients still present at a late stage, perhaps because cancers 
in the early stage are frequently painless.  
 
The treatment of tongue SCC is a multidisciplinary effort. The ability to 
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completely resect tumour with clear surgical margins is critical and directly 
affects survival.6, 7 The choice of adjuvant therapy – radiation or concurrent 
chemo-irradiation depends on the operative findings and histology. In the 
last decade, significant improvement in every field has been made. 
Advances in surgical reconstruction with microvascular free-tissue transfer 
options allow for large tumours to be resected with adequate margins. 
Randomised trials have also demonstrated that the concurrent use of 
cisplatin with post-operation radiation therapy benefits patients with poor 
prognostic features.6, 8, 9 Patients now receive this if adverse histological 
features are present. The delivery of radiation in the form of intensity-
modulated radiation therapy (IMRT) has also effectively allowed for high 
dose radiation to affected area with reduced radiation dose to adjacent 
sensitive structures such as the salivary glands, aerodigestive mucosa and 
spinal cord.10, 11 Despite these advances, SCC of the oral tongue remains 
a disease with significant locoregional recurrence rates and poor survival. 
 
Local and/or regional disease recurs in 50-60% of patients with advanced 
disease treated with combined modality therapy.6, 8 Locoregional 
recurrences result in significant morbidity and mortality as speech and 
swallowing are frequently affected. A percentage of such patients may be 
treated with re-resection. Re-irradiation with or without cisplatin is also 
being explored.  
 
Apart from improvements in the therapeutic fronts, research is being done 
to explore why oral tongue SCC recurs so frequently despite aggressive 
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multimodality therapy, and there is ongoing efforts to seek new molecular 
therapeutic targets. The cancer stem cell theory is a recent development in 
cancer biology that may redefine our understanding and approach to 
treating tongue cancer.  
 
 
1.3 Cancer Stem Cells 
  
Stem cells have the ability to generate large numbers of mature cells 
through a hierarchy of proliferation and differentiation, while retaining the 
ability to self-renew in order to maintain the stem cell pool. Such 
hierarches of development exist both in the embryonic and adult states – 
as pleuripotent cells in the embryo developing into specialized cells, and 
as a repair system for the body to replenish adult tissues. 
 
The cancer stem cell hypothesis suggests that a tumour may be viewed as 
an aberrant organ that is sustained, in a way similar to normal tissues, by 
a subset of biologically distinct stem cells (cancer stem cells). These cells 
constitute a small subset of the tumour and drive tumourigenesis, 
producing both stem cell progenies and differentiated, non-tumourigenic 
progenies that make up the bulk of the tumour (Figure 1).12 This model of 
tumourigenesis challenges the traditional model of carcinogenesis where 
adult somatic cells are thought to acquire the ability to self renew and 
generate a tumour due to the accumulation of multiple mutations. 
Malignant transformation of multiple clones were thought to account for the 
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phenotypic diversity within a tumour, and each cell regarded as having the 
ability to proliferate and metastasize. Should the stem cell theory be true, a 
paradigm change in how we view and treat cancer is in order. The success 
of therapies would no longer be determined by mere shrinkage of tumours 
or metastatic deposits, and not all cells within a tumour should be 
considered equal. Rather, it is this precise subset of cancer stem cells that 
















a) Stochastic model     b) Cancer stem cell model 
  
In the traditional model of tumourigenesis (a), each cancer cell has the 
potential to mutate, proliferate and form a new clone. The cancer stem cell 
model (b) hypothesizes that only the cancer stem cell (red) is able to drive 
tumourigenesis, producing both stem cell progenies and heterogenous 
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A) Therapy does not effectively kill cancer stem cell (red).  
Tumour regenerates despite initial shrinkage. 














B) Therapy that targets cancer stem cells (red) may not shrink 





1.3.1 Evidence for cancer stem cells 
 
The first documentation that only a small subset of cancer cells is capable 
of extensive proliferation leading to tumour formation came from studies of 
acute myeloid leukemia and multiple myeloma. Evidence of leukemic stem 
cells was elegantly demonstrated by Bonnet and colleagues when they 
isolated CD34+CD38- cells from leukemic patient samples and showed 
that only these cells, which constitute a variable proportion of acute 
myeloid leukemic cells – 0.2% in one patient, were able to transfer acute 
myeloid leukemia from patients to Non-obese diabetic severe combined 
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immunodeficient (NOD/SCID) mice.13 This demonstrated conclusively that 
not all cells had similar clonogenic capabilities, and that a specific, 
identifiable group of cells had enriched capacity to form clones while the 
majority of leukemic cells lack the ability to proliferate and transfer 
disease.  
 
Similar observations were made of some solid cancers. In breast cancer, 
similar to leukemia and other hematological malignancies, tumourigenic 
and non-tumourigenic populations of breast cancer cells were isolated 
based on their expression of cell surface markers. In many cases of breast 
cancer, only a small subpopulation of cells, characterized by CD44+CD24- 
had the ability to form new tumours.14, 15 Furthermore, when these 
tumourigenic cells were injected into NOD-SCID mice, the tumours formed 
contained multiple cells lines. This work strongly supported the existence 
of cancer stem cells in breast cancer.14 Further evidence for the existence 
of cancer stem cells occurring in solid tumours has been demonstrated in 
malignancies of the central nervous system (CNS). Using culture 
techniques similar to those used to culture normal neuronal stem cells, it 
was shown that neuronal CNS malignancies contain a small population of 
cancer cells, identified by CD133+ surface expression, that are clonogenic 
in vitro and initiate tumours in vivo. CD133- cells did not exhibit these 
properties. 16 
  
The defining characteristics of this group of cells with stem-like qualities 
are their ability to give rise to a bulk mass of differentiated tumour cells, 
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self-renew on serial transplantation studies, and be able to do so in small 
numbers whereas tumour cells not of this fraction lack this capacity 
despite greater numbers being transplanted. These stem-like cells may be 
identified by specific markers. Fluorescent-activated cell sorting (FACS) 
using specific antibodies directed against cell surface antigens such as 
CD34, CD133 and/or CD44 is a commonly employed technique to sort and 
isolate the small population of cells with stem cell-like properties.15-19 The 
Hoechst dye efflux technique is another method used to isolate the side 
population (SP) cells that are enriched in tumour-initiating capability 
compared to non-SP cells, although it is likely these do not represent a 
pure population of so-called cancer stem cells. Tumours in which such 
side populations of tumourigenic cells have been identified and 
characterized include the CNS, breast, ovary, prostate, pancreas, 
colorectal and head and neck cancers.15-18, 20, 21 
 
 
1.3.2 Pathobiology of cancer stem cells 
 
Having characterized in tumours a sub-population of cells with stem cell-
like properties and christening them as cancer stem cells (CSCs), 
research has sought to better understand this group of highly tumourigenic 
cells. Their origin is itself debated – whether they arise through mutations 
of normal somatic stem cells, or did the malignant stem cell-like 
characteristics develop from an accumulation of genetic mutations and de-
differentiation of mature cells. 
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Work done by Vogelstein and Weinberg estimated that three to six genetic 
mutations are required to induce malignant change to a normal human 
cell.22, 23 In order to become malignant, cells need to exist long enough to 
accumulate these genetic changes – an argument that supports normal 
somatic stem cells as the cells of origin as the hierachical stem cell 
concept indicates that stems cells are the only cells that remain and 
survive long enough to accumulate these mutations. In addition, signaling 
pathways found to be critical for embryonic development and stem cell / 
progenital cell renewal, such as the Notch, Sonic hedgehog (Shh) and Wnt 
signaling pathways are also associated with oncogenesis, suggesting that 
the cells of origin of a cancer stem cell likely already had such self-
renewing capability, thus providing further indirect evidence that cancer 
stem cells arise from normal somatic stem cells.24, 25 Conversely, other 
studies suggest that cancer stem cells may originate through de-
differentiation of mature cells. Keratinocytes that are downstream from 
their progenitor stem cells have been shown both in vivo and in vitro to 
acquire oncogenic events that induce stem cell-like renewal capacity.26, 27 
 
Apart from initiating tumourigenesis, cancer stem cells have also been 
linked with the metastatic dissemination of epithelial cancer cells. The 
epithelial-mesenchymal transition (EMT) is the process where a polarized 
epithelial cell assumes a mesenchymal cell phenotype. It has a crucial role 
in embryogenesis - in the differentiation of various tissues and organs, and 
in tissue repair.28 During EMT, cell-cell and cell-extracellular matrix 
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contacts are broken, and epithelial cells migrate to other locations in the 
body.29 Recent studies have suggested that the activation of signaling 
pathways that induce EMT generates stem cell-like properties in non-
tumourigenic mammary epithelial cells.30, 31 In immortalised human 
mammary epithelial cells, the activation of EMT resulted in the acquisition 
of the CD44+/CD24- stem cell phenotype. In essence, EMT endows cells 
with migratory and invasive properties, induces stem cell properties, and 
prevents apoptosis and senescence. It is implicated in cancer where the 
mesenchymal state is associated with the capacity of cells to migrate to 
distant organs and maintain stem cell qualities, allowing their subsequent 
differentiation into multiple cell types during development and the initiation 
of metastasis. 
 
Besides attempts to characterize the role of cancer stem cells in the 
initiation, progression, invasion and metastasis of cancer, there is also 
much interest in the effect of current therapies upon these cells. If by 
analogy to normal stem cells, cancer stem cells should be inherently 
resistant to chemotherapy and radiation therapy through mechanisms that 
serve to protect stem cells from DNA and cellular damage, they would 
conceivably be resistant to the traditional oncologic treatment strategies of 
radiotherapy and chemotherapy. Tumour recurrences may then be 
attributed to surviving cancer stem cells that have escaped multimodal 
therapy. 
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Phillips et al. provide evidence that CSCs may be intrinsically 
radioresistant.32 In their study, nonadherent cells isolated from two 
established breast cancer cell lines and propagated as mammospheres, 
having a higher fraction of CD24-/low/CD44+ cells (previously identified as 
cancer-iniatiating cells) were compared with adherent cultures. Both cell 
populations were irradiated as single-cell suspensions, removing the 
complicating factor of low oxygen tension at the centre of spheroids. When 
irradiated in vitro, the cells arising from spheroids were more 
radioresistant. Furthermore, fractionated radiation appeared to increase 
the percentage of nonadherent CD24-/low/CD44+ cells in monolayer cell 
cultures, suggesting that the relative radioresistance of this population of 
cells may lead to their expansion after a course of radiotherapy.32 In 
another study, Bao et al. studied xenografts from primary glioblastoma 
multiforme specimens. They found that CD133+ cells (previously 
established to be the tumourigenic population in primary glioblastoma 
multiforme) were radioresistant compared with CD133- cells.33 Importantly, 
they showed that CD133+ cells accumulated after irradiation both in vitro 
and in vivo. In addition, they demonstrated that the modest enrichment of 
CD133+ cells after irradiation has biological relevance by showing that a 
slight increase in the percentage of CD133+ cells in suspensions used to 
initiate tumours dramatically increased their growth rate. The relative 
radioresistance was further explored by investigating molecular markers of 
radiation damage. It was concluded that CD133+ cells could activate DNA 
damage checkpoint responses to a greater degree that CD133- cells and 
thus repair DNA damage more efficiently.33 
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Stem cells from various normal tissues also tend to be more resistant to 
chemotherapeutics than their mature non-stem counterparts. The 
purported reasons include a higher level of antiapoptotic proteins and the 
presence of multidrug resistance (MDR) transporters that reduce the 
plasma membrane permeability to cytotoxic compounds.34, 35 The protein 
glutathione-S-tranferase has also been implicated in intrinsic 
chemoresistance.36 To date, the exact mechanisms of chemoresistance in 
tumour initiating cells have yet to be entirely elucidated, and extrinsic 
factors of the microenvironment may conceivably contribute.36, 37 A better 
understanding of the complex interaction of cancer stem cells and 
chemotherapeutics is therefore essential to avoid tumour relapses driven 
by cancer stem cells having escaped multimodality therapy. 
 
 
1.3.3 Cancer stem cells in Head and Neck Squamous Cell Carcinoma 
 
In head and neck squamous cell carcinoma (HNSCC), Prince et al first 
isolated a highly tumourigenic subpopulation of cancer cells that had 
cancer stem cell properties.20 Using the cell surface antigen CD44 that 
was previously demonstrated to be a useful cell surface marker for breast 
cancer stem cells (CSC), single-cell suspensions from HNSCC specimens 
were stained with an antibody to CD44. Flow cytometry analysis showed 
that HNSCC cells were heterogeneous for CD44 expression, with tumours 
comprised typically of < 10% CD44+ cells. The tumour cells were sorted to 
  19 
purity using fluorescence-activated cell sorting (FACS), and cells with 
CD44 surface antigens and those without were injected into NOD/SCID 
mice. The CD44+ group of cells were highly tumourigenic while the CD44- 
cells were not. In addition, the CD44+ cells formed tumours with a mixture 
of CD44+ and CD44- cells, and serial retransplantation of both populations 
indicated that only the CD44+ population could initiate new tumours in 
vivo.20 This experiment demonstrated that a specific subpopulation 
HNSCC cells, identifiable by their cell surface antigen CD44, had 
tumourigenic potential whereas cells not expressing the cell surface 
antigen were non-tumourigenic. That is, phenotypically distinct 
tumourigenic populations exist within head and neck squamous cell 
tumours. Serial transplantation of the purified subpopulation of CD44+ cells 
generated new tumours, indicating that it is a self-renewing population.20 
Although these CD44+ cells possess properties classically attributed to 
stem cells, the relatively large number of cells (>5000) needed to generate 
a new tumour in immunodeficient mice suggests that perhaps only a 
fraction of cells within population may be true CSCs, and that further 
refinement is likely required to precisely isolate HNSCC cancer stem cells. 
Aldehyde dehydrogenase (ALDH), a cytosolic enzyme, has also shown to 
be a useful marker to identify cancer cells with stem-like qualities in head 
and neck cancer.38 ALDH+ cells from patients with HNSCC showed 
enhanced tumourigenesis and radioresistance when compared to ALDH- 
cells.38, 39 Furthermore, the knockdown of Snail decreased expression of 
ALDH and has been shown to inhibit cancer stem cell-like properties and 
the tumourigenicity of CD44+ALDH+ cells. 39 
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The presence of an identifiable, phenotypically distinct subpopulation of 
tumourigenic cancer stem cells in head and neck cancer has clinical 
implications. It suggests that the presence of small numbers of these cells 
under the right conditions may lead to tumour repopulation and relapse 
whereas large numbers of non-tumourigenic cells may not necessarily be 
harmful. In the treatment of these tumours, attention should then be paid 
to the effective elimination of these cancer stem cells. If indeed they are 
more resistant to radiotherapy and chemotherapy, new treatment 
strategies to target and sensitise these cells may necessary. It would also 
mean a change in the measurement of success of treatment – from 
tumour shrinkage to a measurement of the elimination of cancer stem 
cells. New ways to identify this population of cells in situ in patients are 
thus needed. 
 
The cell surface markers are also important. They may potentially be a 
prognostic marker, or aid in treatment selection. The use of these surface 
markers as a target for therapeutic agents has also been explored.40 In 
essence, a better understanding of the intrinsic and extrinsic mechanisms 
of how these tumourigenic cells resist conventional treatments, self renew 
and metastasize may allow for the development of novel therapies and 
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1.4 CD44 
 
1.4.1 The transmembrane protein: CD44 
 
CD44 is a type I transmembrane protein. It is a ubiquitous, abundant and 
functionally important cell surface receptor. A product of a single gene at 
11p13, CD44 exists as several isoforms. It is encoded by at least 20 
exons, with the first and last 5 being invariably expressed; their product is 
referred to as the “standard” or “haematopietic” form of CD44 (CD44s or 
CD44H correspondingly). Alternative splicing of the remaining intervening 
10 exons give rise to a variety of CD44 isoforms that are named variants 1 
to 10 (v1- v10). The structural diversity of CD44 is further amplified by 
posttranslational glycosylation and glycoaminoglycan attachment.41, 42   
 
CD44 is a molecule of considerable interest as its structural diversity 
confers it a great functional spectrum. As a transmembrane protein, it has 
ligand binding capacity and plays a role in signal transduction pathways. It 
has been shown to mediate homotypic cell-cell adhesion, trigger 
heterophilic adhesion events (eg. between endothelial cells and 
leucocytes), act as a signaling molecule through tyrosine kinases, interact 
with EGFR leading to activation of EGFR-dependent signaling cascades, 
induce cytokine expression, and also induce cell proliferation and 
motility.43-45 CD44 has been shown to be expressed in a wide variety of 
tissues and has been linked with various human diseases and 
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malignancies. In recent years it has also been implicated as a cancer stem 
cell marker.14, 20  
 
CD44 acts mainly as a receptor for hyaluronan – a major component of the 
extracellular matrix.46 Hyaluronan is enriched in many types of tumours, 
and in cancer patients, hyaluronan concentrations are usually higher in 
malignant tumours than in corresponding benign tissue.47 The size of the 
hyaluronan fragment to which CD44 binds provides a physiologically 
important switch between its adhesive and signaling functions.48, 49 Binding 
to hyaluronan polymers usually leads to cell adhesion, while binding to low 
molecular weight hyaluronan, a result of tissue damage and consequent 
degradation of the extracellular matrix, leads to CD44 signaling and 
activation of the immune system.46, 48, 49 The binding of hyaluronan results 
in conformational changes or a redistribution of CD44 in the cell 
membrane and influences CD44-mediated signal transduction.    
 
The cytoplasmic partner molecules of CD44 are the cytoskeleton proteins 
ankyrin and ezrin, radixin and moesin (ERM proteins). These proteins 
regulate cell shape, adhesion, migration and motility. Upon binding with 
hyaluronan, reorganisation of the cytoskeleton is initiated, and CD44 is 
guided to the leading edge of the migrating cells. Experimental work in 
vitro has demonstrated that specific isoforms of CD44 renders metastatic 
potential to non-metastasizing cell lines.50 The role of CD44 in neoplastic 
metastasis was further supported when non-cytotoxic antibodies specific 
for the CD44 variant inhibited formation of secondary foci when injected 
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with tumour cells.51 Biologically, specific hyaluronan-mediated CD44 
activation of signaling events have been implicated in cellular adhesion, 
growth, survival, invasion and migration – all obvious prerequisites for 
metastasis.   
 
 
1.4.2 CD44 as a cancer stem cell marker 
 
The evidence that CD44 is expressed on cancer stem cells is recent, and 
raises the question of its role - as a mere cell surface marker, or having a 
functioning role in conferring stem-like qualities. It has been credited for 
maintaining and modulating the microenvironment of cancer stem cells, 
playing a role in antiapoptosis, conferring chemoresistance and being 
crucial to epithelial-mesenchymal transition.   
 
The microenvironment of normal stem cells, or “niche”, maintains their 
quiescent and undifferentiated state while conferring proliferation and 
differentiation potential. A similar microenvironment exists for cancer stem 
cells. These niches are rich in hyaluronan, and hyaluronan-CD44 
association facilitates maintainance of the necessary tumour matrix.52 As a 
transmembrane proteoglycan, CD44 allows the local concentration of 
glycosaminoglycan-associating proteins, increasing the capacity of these 
ligands to interact with their receptors, thereby lowing the threshold for 
signal transduction. The binding of such ligands, including osteopontin and 
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vascular endothelial growth factor, are of interest in the metastatic 
process.53-55  
 
Apart from maintaining the niche matrix surrounding cancer stem cells, 
CD44 is also involved in critical signal transduction pathways that confer 
stem-like characteristics. There is evidence that hylauronan-CD44 binding 
triggers pathways that lead to the transcription of the oncogenic microRNA 
miR-21 and a tumor suppressor protein (e.g. PDCD4: program cell death 
4) reduction.56 These events initiate the up-regulation of the inhibitor of 
apoptosis (IAP) proteins and mutidrug-resistant protein 1 (MDR1), 
resulting in anti-apoptosis and resistance to chemotherapeutics.56, 57  
 
The abberant activation of epithelial-mesenchymal transition (EMT) 
facilitates metastasis by breakdown of cell-cell and cell-extracellular matrix 
contacts and confer cells the capacity to invade and ultimately metastasize 
to distant sites.29, 58 CD44 and hyaluronan are important in regulating 
EMT.52 In breast cancer cells the EMT phenotype is associated with a 
strong CD44 upregulation, and may be inhibited by CD44-specific 
antibodies.59, 60 The inhibition of hyaluronan synthesis also reduces EMT 
and metastasis formation.61, 62 These findings provide evidence for a role 
for CD44 and hyaluronan in EMT.  
 
CD44 and its isoforms have been studied in various cancers. It has also 
been studied by several groups for its role in head and neck SCCs and in 
the various subsites of HNSCC. Previous studies exploring the clinical 
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significance of CD44 expression in head and neck tumours have shown 
conflicting results. Some reported poorer outcomes with low expression of 
CD44.63-67 Others demonstrated a decreased survival and increased nodal 
metastasis with high CD44 expression.68, 69 With its newly elucidated role 
as cancer stem cell marker in head and neck cancer, it may potentially 
have important clinical implications as a prognostic marker and therapeutic 
target. Yet other studies have described its ubiquitous expression on both 
benign and malignant head and neck epithelial as evidence that its value 







































CD44 is a molecule with a spectrum of functional effects. It has been used 
as a marker for the identification of a subpopulation of cells with 
tumourigenic properties in head and neck cancer, and has been referred 
to as a cancer stem cell marker.  
 
The immunohistochemical expression of CD44 may be indicative of the 
proportion of cancer stem cells within the tumour. It may therefore have 
prognostic significance in the clinical outcomes of patients with oral tongue 
SCC, be a potential biomarker for increased resistance to chemotherapy 





This study aims to confirm that specimens of oral tongue SCC have 
variable immunohistochemical staining of CD44s. It aims to determine if 
CD44s expression is associated with known adverse histopathologic 
features, and if it correlates with the clinical outcomes of survival and 
tumour recurrence and may thus be a prognostic marker. 
 
It also aims to determine if CD44s expression in head and neck SCC is 
associated with clinical response to chemotherapy or radiotherapy. 
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2.1 Initial study design  
 
In order to evaluate if CD44s expression in head and neck SCC correlated 
with clinical response to chemotherapy or radiotherapy, the initial dataset 
and experiments were based on archival tissue of patients who had been 
enrolled in a multicentre prospective randomized trial which investigated 
the use of surgery and adjuvant radiotherapy vs upfront concurrent 
chemoradiotherapy for locally advanced, resectable head and neck 
SCC.71 Patients eligible for the trial had newly diagnosed, histologically 
proven squamous cell carcinoma of the head and neck that were locally or 
regionally advanced, not metastatic, and were deemed resectable. Tumor 
“resectability”, while largely subjective, was determined after clinical and 
radiological evaluation at a multidisciplinary tumor board with input from a 
panel of surgical oncologists, radiologists, medical oncologists and 
radiation oncologists. Tumors from all head and neck subsites except the 
nasopharynx and salivary glands were included. 
 
Patients who met the above criteria had been randomized into the two 
treatment arms: the standard (S) arm consisting of radical surgery with 
adjuvant radiotherapy, and the experimental arm (C) of combination 
chemotherapy (cisplatin and 5-FU) administered concurrently with radical 
radiotherapy. 
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    Soo KC BJC 2005 71 
Figure 3. Trial profile of SHN01, a multicentre prospective randomized trial 
which investigated the use of surgery and adjuvant radiotherapy vs upfront 




  30 
The (S) arm received surgery consisting of wide resection of the tumor 
with frozen section control during the surgical procedure to ensure clear 
margins.  Comprehensive neck dissection with removal of levels I to V 
lymph nodes was performed unilaterally or bilaterally as indicated. 
Adjuvant radiotherapy was given to the primary tumor site and upper neck 
at 2 Gy per fraction, 5 days a week to a total of 60 Gy in 30 fractions over 
6 weeks. Radiation therapy commenced as soon as adequate healing had 
been established, and not more than 6 weeks after surgery. Fields were 
reduced to exclude the spinal cord at 40 Gy and a posterior electron-
matching field was applied. The dose to clinically uninvolved nodal region 
was 50 Gy. In patients with disease extending low down the neck, an 
anterior based AP/PA field was treated to a dose of 50 Gy, followed by 
lateral fields in another 10 Gy that did not include the spinal cord in the 
treatment volume. Patients who had positive surgical margins had the 
dose to the area at risk escalated to 70 Gy using reduced volumes. The 
lower anterior neck was treated if there was nodal disease present in the 
upper neck at 2 Gy per fraction to a total of 50 Gy in 25 fractions over 5 
weeks.  
 
Patients randomized to the (C) arm received radiotherapy similar to the (S) 
arm except that the total dose to the primary tumor and upper neck was 66 
Gy in 33 fractions over six and a half weeks, with involved nodes receiving 
at least 60 Gy of radiotherapy. Two cycles of chemotherapy consisting of 
cisplatin 20mg/m2/day and 5-fluorouracil 1000mg/m2/day were given as a 
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continuous intravenous infusion over 96h on days 1 and 28 of 
radiotherapy. 
 
Patients who received concurrent chemoradiotherapy underwent 
examination under anesthesia 6-8 weeks post treatment to evaluate tumor 
response. A complete response is achieved if there was complete 
disappearance of all clinically detectable tumour. Patients with persistent 
disease at the primary site were offered salvage surgery. All patients who 
had nodal disease at the onset would undergo elective neck dissections 
regardless of response to concurrent chemoradiotherapy. 
 
Upon completion of primary treatment, the patients were followed monthly 
for the first year, two monthly for the second year, three monthly for the 
third and six monthly thereafter by all members of the multidisciplinary 
treatment team. Clinical examinations were performed at each visit with 
radiological investigations done when indicated. Suspected recurrences 
were biopsied and patients who developed locoregional disease 
subsequently were considered for appropriate salvage surgery. 
 
Between 19 August 1996 to 21 February 2002, 119 patients were recruited 
to this clinical trial. Sixty patients were randomized to undergo surgery with 
adjuvant radiotherapy (S). Fifty-nine patients were assigned to primary 
treatment by concurrent chemoradiation (C). A review of these patients’ 
pathological and clinical data including follow-up information was obtained 
from the National Cancer Centre Singapore head and neck cancer 
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database and electronic medical records. By July 2008, the median follow 
up time for the (S) arm was 7.1 years (range: 0.1 to 11.4 years) and that 
for the (C) arm, 8.7 years (range: 0.2 to 11.3 years). 
 
Archived hematoxylin and eosine (H&E) histopathologic sections of tumour 
tissue from the trial patients were retrieved. Histological sections of the 
surgical specimens were examined by a senior consultant pathologist 
(HJS) and the most representative section of tumour was identified. For 
patients who had been randomized to upfront concurrent 
chemoradiotherapy, only the biopsy specimen of the tumour were 
available. The appropriate formalin-fixed, paraffin-embedded (FFPE) 
tissue blocks were then retrieved.    
 
Microtome sectioning of the FFPE specimens were performed and 4um- 
thick sections were mounted on Super Frost/Plus-slides (Menzel, 
Braunschweig, Germany). To facilliate adhesion, the slides were dried by 
incubating for 12 h at 37C then at 60C for an hour. Sections were 
deparaffinised in xylene and rehydrated in a decreasing alcohol series. 
 
Immunohistochemical validation was performed on a range of normal 
tonsillar tissue and achival head and neck SCC tumours. Unfortunately, 
attempts to optimize the immunohistochemical protocol for CD44s staining 
on the archival tissue failed. The main problem encountered was a 
consistent lack of staining on all the archived tissue. We employed heat-
induced epitope retrieval (HIER) techniques using microwave heating, 
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vegetable steamers and water baths with varying pH buffers, epitope 
retrieval solutions, time and temperature combinations. Good staining on 
the positive controls (tonsillar tissue from 2008) were consistently obtained 
despite corresponding lack of staining of the all the archival tissue. Such 
disconcordance suggested that the problem was not from ineffective 
antigen retrieval, inactive antibodies or errors in the IHC protocol. It was 
likely that unalterable conditions of the archived tissue, such as 
inadequate fixation techniques, or epitope alterations during embedding 
with resultant failure to restore immunoreactivity accounted for the lack of 
staining. The fact that minimal tissue was available for the patients who 
underwent primary concurrent chemoradiation therapy (patients only had 
diagnostic biopsies) further compounded the difficulties in optimizing a 
suitable protocol. A decision was then made to use a different set of 
patients to investigate the correlation of CD44s expression with 
histopathological features and survival outcomes.  
 
In the formulation of a new experimental plan, the following factors were 
considered. Firstly, tissue from one subsite within the head and neck was 
desired. This would minimize the confounding effect of inherent 
heterogeneity between the different subsites. Secondly, adequate tissue 
samples of the primary tumour should be available. Thirdly, specimens 
from the recent past should be used to minimize significant differences in 
fixation and embedding techniques and loss of epitopes with prolonged 
(possibly suboptimal) storage.  
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As such, we decided to investigate the expression of CD44s expression in 
oral tongue SCC. By restricting tumours to one subsite of the head and 
neck, the biases that may influence survival outcomes are minimized. 
Also, oral tongue SCC is the most common head and neck cancer, and 
any significant finding potentially has greatest clinical impact. Furthermore, 
the mainstay of treatment of oral tongue SCC to date is primary surgical 
resection, and adequate tumour tissue from an enbloc resection would be 
available.  
 
To avoid similar problems with epitope retrieval, hypothesized to be due to 
poor fixation techniques in the 1990s and suboptimal, prolonged storage, 
we retrieved a random sample of 10 oral tongue specimens from the 
recent years of 2002 and 2003. These years were also selected as 
patients from then would provide adequate follow up data for meaningful 
survival analyses. We did a trial of IHC staining for CD44s, and a protocol 
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2.2 Patients and specimens 
 
The current study is based on formalin fixed, paraffin embedded (FFPE) 
histopathological specimens from consecutive patients with oral tongue 
squamous cell carcinoma treated with radical excision of the primary 
tongue lesion at the Department of Surgical Oncology, National Cancer 
Centre Singapore and Department of General Surgery, Singapore General 
Hospital, within the period of January 2002 – December 2005. A 
retrospective review of these patients’ pathological and clinical data 
including follow-up information was obtained from our Head and Neck 
Cancer Database and electronic medical records.  
  
For the purpose for this study, we included all patients with histologically 
proven SCC oral tongue treated with surgical resection upfront. Patients 
with non-SCC tongue cancers, non-tongue SCC cancers of the head and 
neck, those with incisional biopsies only, or had prior treatment with 




The hematoxylin and eosine (H& E) stained histopathologic sections of the 
surgical specimens were examined by a senior consultant (HJS) at the 
Department of Pathology, Singapore General Hospital. A representative 
section of the primary tongue SCC was identified and the corresponding 
FFPE block retrieved. For immunohistochemistry, 4-um thick sections 
  36 
were mounted on Super Frost/Plus-slides (Menzel, Braunschweig, 
Germany) and incubated at 60C for an hour then at 37oC for 12 hours. 
The histological sections were deparaffinised in xylene and rehydrated in a 
decreasing alcohol series. The sections were then submitted to antigen 
retrieval by steaming for 20 mins in a commercial Epitope Retreival 
Solution (Tris/EDTA-based buffer pH9 Novocastra, Wetzlar, Germany) 
and cooled for 20 mins. The samples were then washed with phosphate-
buffered saline (PBS, pH 7.2) twice for 3 minutes on a belly dancer. Each 
histologic section upon the slides was then outlined with a delimiting pen 
(Dako, Glostrup, Denmark). Endogenous peroxidases were blocked by 
3% peroxidase treatment for 15 min. The samples were again washed in 
PBS for 5 min then incubated in 1.5% horse serum for 30 min to prevent 
non-specific antibody binding. A monoclonal mouse antibody with 
specificity to CD44s (Novocastra NCL-CD44-2, Wetzlar, Germany) 
diluted to 1:100 with Tris-buffered saline (IHC Diluent, Novocastra 
RE7133, Wetzlar, Germany) was used as the primary antibody. The slides 
were incubated for 30 min at room temperature then washed with PBS and 
further incubated with Dako REALEnVision Detection System for 30 
min (Dako, Glostrup, Denmark). Immunostaining was visualized with 3,3- 
diaminobenzidine for 5 min and the reaction was stopped by washing in 
running water. Counterstaining was performed with hematoxylin, 
dehydrated and mounted with DePex (BDH Ltd, Poole, UK). In each 
staining series, a known CD44s positive tongue SCC specimen served as 
a positive control and the same tongue SCC section processed as per 
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protocol but without primary antibody incubation served as a negative 
control. 
 
All tumours were re-evaluated for histological type, grade and 
immunohistochemical staining by a senior consultant histopathologist 
blinded to the clinical data. The immunoreactivity of the tumour cells for 
CD44s was scored according to the percentage of CD44s staining (score 
ranging from 0% to 100%), and the intensity of all cells that had a positive 
staining was estimated on a semi-quantitative three-grade scale from 1 to 
3+ (1: weak staining, 2: moderate staining, 3: strong staining).  
 
 
2.4 Statistical analysis 
 
Comparisons of CD44s intensity between patients in different 
histopathological characteristic groups were performed using either the 
Chi-square test or Fisher’s exact test as appropriate.  
 
Mann-Whitney U test was used to detect any significant differences in the 
CD44s percentage between patients with and without the presence of 
angioinvasion, perineural invasion or nodal disease.   
 
Kruskal-Wallis test was used to compare CD44s percentage between 
patients in the 3 tumour grade groups (well-differentiated, moderately 
differentiated and poorly differentiated).  
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The Kaplan-Meier method was used to estimate all survival distributions, 
and the log-rank test was used to test the differences between survival 
curves. Cox proportional hazard models were fitted to estimate hazard 
ratios to assess association of factors with each endpoint.   
 
The definitions of the clinical endpoints used are as follows: 
 
 Overall survival (OS) is the duration from index treatment (surgery) 
to death from any cause. Alive patients were censored at their date 
of last follow-up.  
 
 Disease-free survival (DFS) is the duration from surgery to first 
relapse, irrespective of site. Dead patients without disease 
recurrence were censored at their dates of death. Alive patients 
without evidence of the relapse measured were censored at their 
date of last follow-up. 
 
 Distant Metastases-free interval (DMFI) is the duration from surgery 
to first distant metastasis. Dead patients without disease recurrence 
were censored at their dates of death. Alive patients without 
evidence of the relapse measured were censored at their date of 
last follow-up. 
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 Locoregional Recurrence-free Interval (LRFI) is the duration from 
index treatment to first locoregional relapse. Dead patients without 
disease recurrence were censored at their dates of death. Alive 
patients without evidence of the relapse measured were censored 





The research plan was approved of by the institution review boards (IRB) 
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3.1 Clinical data 
 
Fifty-one oral tongue squamous cell carcinoma patients were included in 
the study population. The median age was 57 years (range 18 – 89 years). 
There were more males (69%) than females. Twelve tumours (24%) were 
well differentiated, 35 (68%) moderately differentiated and 4 (8%) poorly 
differentiated. Twenty-five patients (49%) had nodal metastasis.  
 
Among patients with non-missing data, 19 patients (49%) had perineural 
invasion and 8 (19%) had angioinvasion. Most patients had negative 
surgical margins (46 patients, 92%), and 20 (39%) patients had adjuvant 
therapy. Among the patients receiving adjuvant therapy, 14 (70%) were 
treated with radiotherapy and the remaining 6 (30%) had concurrent 
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Table 1. Demographic and histopathologic characteristics of all patients 
 
 







   
Age at index treatment, years   
   Median 57.0 
   Range 18.8 – 89.7 
   
Gender   
   Female 16 31.4 
   Male 35 68.6 
   
T stage*   
   T1 17 33.3 
   T2 24 47.1 
   T3 8 15.7 
   T4a 2 3.9 
   
Nodal disease   
   No 26 51.0 
   Yes 25 49.0 
   
Overall stage*    
   I  12 23.5 
   II 11 21.6 
   III 12 23.5 
   IVA 16 31.4 
   
Angioinvasion   
   No  35 81.4 
   Yes 8 18.6 
   
Perineural invasion   
   No  20 51.3 
   Yes 19 48.7 
   
Tumour grade    
   Well differentiated  12 24.0 
   Moderately differentiated  34 68.0 
   Poorly differentiated  4 8.0 
   
Resection margins   
   Negative  46 92.0 
   Positive  4 8.0 
   
Adjuvant therapy    
   No 31 60.8 
   Yes 20 39.2 
   
Among patients with adjuvant therapy: 20 100.0 
   Radiotherapy 14 70.0 
   ChemoRT 6 30.0 
  
Follow-up since index treatment, years  
   Median 4.2 
   Range 0.1 – 8.9 
 
*Based on AJCC version 6 pathological staging. 
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3.2 Expression of CD44s in oral tongue SCC 
 
Microscopically, the oral tongue SCCs demonstrated proliferation of 
malignant epithelial cells arranged in solid sheets, nests, islands and cords 
invading the connective tissue with a variable degree of keratinization. 
 
Immunoexpression of CD44s was noted in all oral tongue SCC specimens 
studied. The pattern of cellular distribution was membranous, and CD44s 
was expressed both by tumour epithelial cells and basal cells of 
keratinocytes.  
 
CD44s expression was classified according to intensity of tumour cell 
staining, based on a semi-quantitative visual estimate to a 3-point scale 
(strong 3+; moderate 2+; weak 1+) (Figure 4), and percentage of tumour 
cells expressing CD44s. The median percentage of immunohistochemical 
staining of CD44s was 50% (range 5% to 100%). Strong staining intensity 
was demonstrated in 52.9%, moderate staining intensity in 41.2%, and 
5.9% stained weakly for CD44s (Table 2).  
 
Table 2. IHC expression of CD44s in oral tongue SCC specimens 







   
Intensity    
   Weak 3 5.9 
   Moderate  21 41.2 
   Strong 27 52.9 
      
Percentage    
   Median  50 
   Range 5 – 100  








Figure 4. Immunohistochemical expression of CD44s in oral tongue SCC  

































c) Weak IHC staining intensity of CD44s (1+ intensity) 
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3.3 Correlation of CD44s expression with histopathologic features 
The association of CD44s expression, both intensity of staining and 
percentage staining, with the following histopathological characteristics 
were examined (Table 3): 
 Tumour grade (1: well differentiated, 2: moderately differentiated, 3: poorly 
differentiated) 
 Presence of nodal disease 
 Angioinvasion 
 Perineural invasion 
There was no significant association between CD44s staining percentage 
or intensity with histopathologic characteristics such as presence or 
absence of nodal metastasis, angioinvasion or perineural invasion.  
 
Tumours that were moderately or poorly differentiated were more likely to 
show strong CD44s staining than well-differentiated tumours (60.5% vs 
33.3 %, p = 0.08), although this did not reach statistical significance. 
 
Table 3. Association of CD44s expression with histopathologic characteristics  
 Tumour Grade 
 Total Well  
differentiated  




No % No % No % 
Total 50 100.0 12 100.0 38 100.0  
        
Intensity        
   Weak 3 6.0 2 16.7 1 2.6 0.08 
   Moderate  20 40.0 6 50.0 14 36.8 
   Strong 27 54.0 4 33.3 23 60.5 
        
Percentage        
   Median 45 40 45 0.72 
   Range 5 – 100  10 – 100  5 – 90  - 
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No % No % No % No % 
Total 50 100.0 12 100.0 34 100.0 4 100.0  
          
Intensity          
   Weak 3 6.0 2 16.7 1 2.9 0 - 0.28 
   Moderate  20 40.0 6 50.0 13 38.2 1 25.0 
   Strong 27 54.0 4 33.3 20 58.8 3 75.0 
          
Percentage          
   Median 45 40 40 90 0.32 
   Range 5 – 100  10 – 100  5 – 90  10 – 90  - 
  
 Presence of Nodal Disease 
Total No Yes P-value 
No % No % No % 
Total 51 100.0 26 100.0 25 100.0  
        
Intensity        
   Weak 3 5.9 3 11.5 0 - 0.32 
   Moderate  21 41.2 10 38.5 11 44.0 
   Strong 27 53.0 13 50.0 14 56.0 
        
Percentage        
   Median 50 40 50 0.30 
   Range 5 – 100  5 – 100  10 – 90  - 
  
 Presence of Angioinvasion 
Total No Yes P-value 
No % No % No % 
Total 43 100.0 35 100.0 8 100.0  
        
Intensity        
   Weak 3 7.0 2 5.7 1 12.5 0.38 
   Moderate  17 39.5 13 37.1 4 50.0 
   Strong 23 53.5 20 57.1 3 37.5 
        Percentage        
   Median 40 50 30 0.10 
   Range 5 – 100  5 – 100  10 – 80 - 
  
 Presence of Perineural Invasion 
Total No Yes P-value 
No % No % No % 
Total 39 100.0 20 100.0 19 100.0  
        
Intensity        
   Weak 2 5.1 2 10.0 0 - 0.21 
   Moderate  16 41.0 6 30.0 10 52.6 
   Strong 21 53.8 12 60.0 9 47.4 
        Percentage        
   Median 50 50 40 0.76 
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3.4 Correlation of CD44s expression with clinical outcomes 
 
Survival data was analysed for all 51 patients included in the study 
population.  
 
The median follow-up time was 4.2 years (range 0.1 – 8.9 years). 
Univariate Cox regression analysis was performed to assess the strength 
of association of each clinicopathological parameter and CD44s 
expression (percentage staining and intensity) with overall and disease-
free survival, as well as distant recurrence-free and locoregional 
recurrence-free intervals. 
 
3.4.1 Overall Survival   
 
Strong intensity of immunohistochemical staining for CD44s and the 
presence of nodal metastases were identified as possible prognostic 
factors on univariate analysis (Table 4). On multivariate analysis, strong 
staining was found to be independently associated with improved overall 
survival and the presence of nodal metastases was an independent poor 
prognostic factor after adjustment for the relevant covariates (Table 5). 
 
Kaplan-Meier survival curves indicate that strong CD44s expression  had 
significantly better overall survial compared to those with moderate/weak 
staining (log rank P = 0.04, Figure 5). 
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Table 4. Univariate Cox regression analysis for overall survival 







    
CD44s intensity 
(strong) 
0.32 0.10-1.03 0.06 
    
CD44s percentage 0.99 0.97-1.01 0.20 
    
Gender (male) 0.53 0.19-1.50 0.23 
    
T stage (T3/4a vs T1/2) 2.22 0.76-6.53 0.15 
    
Nodal mets (present) 2.81 0.94-8.35 0.07 
    
Stage (III/IVa vs I/II) 2.11 0.71-6.27 0.18 
    
Angioinvasion 1.42 0.44-4.57 0.55 
    
Perineural invasion 1.79 0.60-5.37 0.30 
    
Resection margins 
(involved) 
2.43 0.67-8.78 0.18 
    
Adjuvant therapy 0.99 0.35-2.78 0.98 
    
 
 
Table 5. Multivariate Cox regression analysis of overall survival 







CD44 intensity  Weak / Moderate 11 / 24 1 0.028 
Strong 4 / 27 0.27 (0.09 – 0.87) 
     
Nodal disease  No 5 / 26 1 0.030 











Figure 5. Kaplan-Meier estimate of overall survival in oral tongue SCC based on 
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3.4.2 Disease-free interval 
Univariate analysis was performed to assess the strength of association of 
each clinicopathological paramter and CD44s expression with disease-free 
interval. Angioinvasion and the presence of nodal metastases were 
identified as likely significant independent prognostic factors (Table 6). On 
multivariate analysis, the presence of angioinvasion showed to be an 
independent poor prognositic factor for disease-free interval, while the 
presence of nodal metastases was not significantly associated with 
disease-free interval (Table 7).   
 
Table 6. Univariate Cox regression analysis for disease-free interval 







    
CD44s intensity 
(strong) 
0.79 0.33-1.85 0.58 
    
CD44s percentage 1 0.98-1.01 0.52 
    
Gender (male) 0.49 0.20-1.19 0.12 
    
T stage (T3/4a vs T1/2) 1.10 0.37-3.28 0.87 
    
Nodal mets (present) 2.29 0.94-5.55 0.067 
    
Stage (III/IVa vs I/II) 1.65 0.68-4.00 0.27 
    
Angioinvasion 3.77 1.46-9.70 0.006 
    
Perineural invasion 1.70 0.67-4.34 0.26 
    
Resection margins 
(involved) 
1.24 0.29-5.38 0.77 
    
Adjuvant therapy 0.84 0.35-2.02 0.69 
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Table 7. Multivariate Cox regression analysis for disease-free interval 
Variable Categories No of events / patients HR (95% CI) P-value^ 
Nodal disease No 8 / 21 1 0.635 
Yes 12 / 22 1.27 (0.48 – 3.34) 
     
Angioinvasion 
 
No 13 / 35 1 0.018 
Yes 7 / 8 3.43 (1.24 – 9.47) 
 
 
The immunohistochemical expression of CD44s is not associated disease-
free interval. Figure 6 shows the Kaplan Meier estimate of strong staining 
intensity of CD44s vs moderate/weak staining intensity (Log-rank P = 
0.58).  
 
Figure 6. Kaplan-Meier estimate of disease-free interval in oral tongue SCC 
based on CD44s staining intensity – strong vs moderate/weak staining. Log 
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3.4.3 Distant metastasis-free interval 
 
The risk of distant metastasis was lowered by 4% with every unit increase 
in CD44s percentage staining (HR 0.96, 95% CI 0.92 – 1.00; P =0.08) 
(Table 8). The other variables analysed were not associated with distant 
metastasis-free interval. 
 
Table 8. Univariate Cox regression analysis of distant metastasis-free interval 







    
CD44s intensity 
(strong) 
0.19 0.02-1.59 0.12 
    
CD44s percentage 0.96 0.92-1.00 0.08 
    
Gender (male) 0.75 0.14-4.09 0.74 
    
T stage (T3/4a vs T1/2) 2.37 0.43-12.9 0.32 
    
Nodal mets (present) 2.87 0.52-15.7 0.23 
    
Stage (III/IVa vs I/II) 2.13 0.39-11.7 0.38 
    
Angioinvasion 0.84 0.10-7.22 0.88 
    
Perineural invasion 1.42 0.28-7.11 0.67 
    
Resection margins 
(involved) 
2.09 0.24-17.9 0.50 
    
Adjuvant therapy 1.46 0.29-7.25 0.64 
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Kaplan-Meier estimates of distant-metastasis free interval showed no 
difference between strong staining intensity and moderate/weak staining 




Figure 7. Kaplan-Meier estimate of distant metastasis-free interval in oral 
tongue SCC based on CD44s staining intensity – strong vs moderate/weak 
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3.4.4 Locoregional recurrence-free interval 
 
 
On univariate analysis, strong CD44s expression correlated with improved 
locoregional recurrence-free interval (HR 0.25 95%CI 0.07-0.93, p=0.53). 
The presence of angioinvasion is also a poor prognostic factor for LRFI 
(HR 3.79 95%CI 1.34 – 10.72, p=0.012) (Table 8). On multivariate 
analysis, both remained independently associated with locoregional 
recurrence-free interval after adjustment for covariates (Table 9).  
 
 
Table 9. Univariate Cox regression analysis for locoregional recurrence-free interval 
 







    
CD44s intensity 
(strong) 
0.25 0.07-0.93 0.053 
    
CD44s percentage 1.0 0.98-1.02 0.962 
    
Gender (male) 0.44 0.17-1.16 0.095 
    
T stage (T3/4a vs 
T1/2) 
0.56 0.13-2.46 0.443 
    
Nodal mets 
(present) 
1.47 0.57-3.84 0.428 
    
Stage (III/IVa vs 
I/II) 
1.08 0.42-2.82 0.871 
    
Angioinvasion 3.79 1.34-10.7 0.012 
    
Perineural invasion 1.38 0.48-3.97 0.546 
    
Resection margins 
(involved) 
0.68 0.09-5.17 0.711 
    
Adjuvant therapy 0.75 0.28-2.03 0.569 
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Table 10. Multivariable Cox regression analysis of locoregional recurrence-free interval 
 







CD44 intensity  Weak 3 / 3 1 0.029 
Moderate  5 / 17 0.12 (0.03 – 0.59) 
Strong  8 / 23 0.22 (0.05 – 0.87) 
     
Angioinvasion No 10 / 35 1 0.004 
Yes 6 / 8 5.40 (1.74 – 16.76) 
 
 
The Kaplan-Meier survival plot of locoregional recurrence-free interval by 
CD44s staining intensity is shown in figure 8. There is a statistical 
significance in LRFI between patients with different CD44s staining 
intensity. (Log-rank P = 0.029) 
 
Figure 8. Kaplan-Meier estimate of locoregional recurrence-free interval in 
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4.1 Association of CD44s expression with histopathological features 
 
 
Since CD44 has been associated with head and neck cancers, its function 
has been of great interest to researchers. Its purported roles have ranged 
from being a cell-surface docking receptor having a role in cell-cell 
adhesion, to being an initiator of metastasis and even as a cell surface 
marker for head and neck cancer cells with stem-like qualities. Its exact 
function has yet to be defined, and researchers have studied this aspect 
extensively. As a starting point in elucidating the role of CD44, 
investigators have often explored the expression of CD44 with 
histopathological features. In the treatment of head and neck cancers, 
several histopathological features are known to be associated with a 
poorer outcome. These adverse features are commonly used as 
surrogates to indicate an aggressive biology, and adjuvant therapy is 
accordingly tailored to include chemotherapy with radiotherapy for better 
disease control. They include tumour grade, nodal metastases, 
extracapsular nodal spread, angioinvasion and perineural invasion.  
 
A systematic review of the available studies investigating CD44 expression 
in head and neck cancers located 8 studies that sought to determine if 
CD44 expression correlated with any histopathologic features. These 
studies varied in the tumour subsites being investigated, CD44 isoform 
being identified, as well as the method of identification and scoring 
parameters. They were similar in that CD44 (or its isoforms) expression 
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was quantified, and statistical methods were used to find associations with 
various histological or staging parameters. 
 
We investigated if CD44s expression by immunohistochemistry, either 
intensity of staining or percentage staining, was associated with the 
aforementioned adverse histopathological features and found no 
significant association with any of the adverse histological features. There 
was a trend towards an association with tumours that were moderately or 
poorly differentiated being more likely to show strong CD44s staining than 
well-differentiated tumours (61% vs 33 %, p = 0.083), but this did not 
reach statistical significance. 
 
Similar to our study, two studies Kawano et al and Gonzales-Moles et al 
found no association between CD44 expression and histopathological 
features.67, 69 Kawano et al attempted to study both clinical outcome and 
histologic association of CD44s and CD44v6 in 57 oropharyngeal 
carcinomas. Most of their patients underwent surgery and radiotherapy, 
and the follow up ranged from 5 to 129 months. Kawano and coworkers 
found that CD44s and CD44v6 mainly stained the basal lamina and fibrous 
connective tissue, and semi-quantitative scoring (<5%; 6-25%; 26-50% 
and >50%) separated the tumours into 4 groups. No significance between 
staining and tumour grade or stage were found.69 In the study by 
Gonzales-Moles et al, 36 tongue SCCs were assessed. Standard CD44 
was stained for, and only cells with membrane staining were counted. 
Expression was categorized as low (<50% of tumour cells) or high (>50% 
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of tumour cells). The authors found no association between CD44s 
expression and histopathology.67 
 
Several researchers have reported that low expression, or down-regulation 
of CD44 is associated with advanced tumour grade and nodal 
metastasis.63-66 These outcomes have largely been attributed to the role of 
CD44 as a cell-cell adhesion molecule, where its down-regulation may 
result in cell detachment with consequent metastasis to the lymph 
nodes.63-66  
 
In brief, Kosunen et al. categorised CD44 expression by the intensity (1+ 
to 4+) and distribution of staining (homogenous vs irregular). 138 samples 
of oral squamous cell cancer were analysed. Irregular staining of CD44 
was associated with poor tumour differentiation and a worse clinical 
stage.63 Sato et al. studied specifically the expression of CD44v9 in 120 
specimens of SCC tongue. CD44v9 expression was grouped according to 
staining patterns in nests of tumour cells. Three groups were defined: all 
cells in the periphery of nests were distinctly positive, a reduction in 
expression in the periphery of tumour nests, and completely negative 
expression in one or more nests.  This group found that decreased 
expression of CD44v9 was associated with increased lymph node 
metastasis. They postulated that the CD44v9 molecule may play an 
important role in cell-cell adhesion, and its downregulation may result in 
cell detachment from tumour nests and subsequent metastasis.64 Stoll et 
al. studied the expression of 5 CD44 isoforms (v4, v5, v6, v7, v9) in 99 
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primary, non-metastatic, oral and oropharyngeal SCC. Tumours were 
evaluated at 100-fold magnification. Cells were counted at each high-
powered field and a tumour was deemed to have a down regulation of 
CD44 if expression of CD44 was less than 50%. A decreased expression 
of CD44v9 was found to correlate with higher histological grade.65 Rodrigo 
and co-workers looked at CD44s and CD44v6 in 101 laryngeal tumours. 
CD44 expression was based on the percentage of cells with membranous 
staining (0-100%). Both CD44s and CD44v6 downregulation were 
associated with poorer differentiation in the tumours.66  
 
Other groups have reported directly conflicting data, where up-regulation, 
or strong CD44 expression is associated with the malignant phenotype. 
Joshua et al. recently evaluated the association of histopathologic features 
with CD44 expression using FACS to determine the percentage of tumour 
expressing the cell surface antigen, CD44.72 Twenty-two squamous cell 
carcinomas from various sites of the head and neck were examined. They 
noted a trend towards an inverse correlation between tumour grade and 
mean CD44+ frequency, that is, tumours with a greater percentage of cells 
expressing CD44 tended to be of poorer differentiation.72 This finding was 
similar to that noted in our series of 51 oral tongue SCCs. This group also 
noted that a higher frequency of CD44+ cells was found in patients with 
perineural and angiolymphatic invasion, but these trends were not found to 
be statistically significant.72  
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Mori and coworkers wanted to establish the role CD44 as a biological 
marker for metastasis. The association between CD44 expression and 
lymph node metastasis was compared in 86 specimens of tongue SCC.68 
Among the 54 cases that had strong staining, 44.4% had metastatic 
disease. Compared with 23.3% with metastatic disease in weak staining 
and no metastasis in tumours with no CD44 staining, a statistically 
significant association between high CD44 expression and increased 
lymph node metastasis was found. Although this study did not directly 
explore clinical outcome, lymph node metastasis has been established as 
an independent prognostic factor for survival in HNSCC. Recent research 
has shed light on the functional effects of CD44 as a adhesion/homing 
molecule involved in pro-oncogenic signaling pathways and being linked to 
the metastatic potential of many cancers.73 The process of cancer 
metastasis is best thought of as an orchestrated series of steps that 
depend first on the growth and invasive potential of the primary tumour. In 
a cancer, cells first lose adhesiveness and detach from the primary site. 
These detached, viable cells – metastatic cells, then penetrate the 
lymphatic and vascular systems by transendothelial migration and 
circulate until adhesion molecules and chemoattractants induce 
extravasation and cell accumulation in a distant organ to establish a 
metastatic deposit. While the binding capacity of CD44 has been invoked 
to support a decreased detachment of tumour cells, and hence decreased 
metastatic potential, the functional effects of CD44 binding to its various 
ligands- hyaluronan, collagen, fibronectin, growth factors etc, have been 
linked to an increased migratory capacity and vascular invasiveness.74 In 
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further support of its role in cancer dissemination, CD44 has also been 
associated with epithelial-mesenchymal transition, and the inhibition of 
CD44 with specific antibodies reduces EMT and metastasis formation.73 It 
also has a role in directing homing of circulating tumour cells to permissive 
metatstatic sites, and is currently being investigated as a therapeutic target 
to prevent metastasis.75 
 
A summary of the studies that investigated CD44 expression and its 


































  64 
Table 11. Studies that examined the association of CD44 expression in head and neck 
SCC with histopathological features 
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4.2 CD44s as a prognostic marker 
 
The prognostication of oral tongue SCC is to date based upon 
clinicopathological grading systems such as the TNM staging of the AJCC 
classification. However, survival varies significantly even within these 
groups, and new biological markers to more accurately predict outcomes 
are constantly explored. CD44, a putative HNSCC cancer stem cell 
marker, a molecule implicated with tumour progression and metastasis, 
and with an apparent key role in cell-cell / cell-matrix adhesion make it an 
interesting candidate for study as a prognostic marker. 
 
We looked at four clinical outcomes of importance – overall survival, 
disease-free interval, distant disease-free interval and locoregional 
disease-free interval. In the management of head and neck cancers, 
perhaps more than in cancers of other organs, the ability to afford good 
locoregional control is paramount as the functional deficits with tumour 
recurrence often directly affect speech and swallowing with resultant 
significant morbidity and mortality.  
 
Regression analyses were performed to determine if gender, tumour size, 
nodal status, disease stage, angioinvasion, perineural involvement, 
adjuvant therapy or CD44s expression (intensity and percentage staining) 
were associated with the four survival outcomes of interest.  
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The immunohistochemical expression of CD44s in oral tongue SCC was 
found to have prognostic significance. Staining intensity of CD44s was 
shown to be a better prognostic marker than the percentage of CD44s 
positive cells. Strong CD44s staining was associated with better overall 
survival when compared with weak/moderate staining intensity. Strong 
CD44s staining was also associated with better locoregional recurrence-
free interval and remained an independent positive prognostic factor on 
multivariate analysis.  
 
Our findings, that strong staining intensity of CD44s is an independent 
positive prognostic marker for overall and locoregional disease-free 
survival, are in conflict with our expectations that as a cancer stem cell 
marker, a greater expression of CD44 would be a poor prognostic marker. 
According to the cancer stem cell theory, a higher stem cell burden, as 
reflected by greater CD44s expression, should correlate with a worse 
outcome in terms of recurrence and survival. However, this is clearly not 
the case and it is likely that high CD44s expression detected through our 
technique is a reflection of an alternative function of CD44 in the cell. 
 
A review of published studies that examined CD44 expression with 
survival outcomes yielded, again, conflicting results. Studies that reported 
similar findings to the current series showed weak staining, irregular 
staining or low expression of CD44 to be a poor prognostic marker for 
disease recurrence or overall survival.63-67 In contrast, a recent study by 
Lindquist et al examined 102 oropharyngeal (tonsil and base of tongue) 
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SCC to determine CD44s expression using IHC.76 Similar to our study, 
both the intensity of staining and percentage of positively stained cells 
were evaluated by a senior pathologist and semi-quantitatively into 4 
groups each (Intensity of staining: 0 to 3+ equal to absent, mild, moderate 
and strong; Percentage of positive cells scaled to  0, 1-10%, 11-49%, and 
>50%). They found on multivariate analysis that a high intensity of CD44 
staining was a strong, independent indicator of a poor prognosis.76  
 
A tabulated summary of the studies that investigated CD44 expression 
with clinical outcomes is presented in Table 12.  
 
One of the dilemmas in reviewing the literature on CD44 as a potential 
biomarker for HNSCC is the variability of the parameters investigated. The 
3 main variables are:  firstly, the CD44 isoform being investigated; 
secondly, the method of determining CD44 expression; thirdly, the tumour 
subsite within the head and neck. 
 
CD44 is a molecule with great structural diversity. It has multiple isoforms 
and undergoes posttranslational modifications with resultant multiplicity of 
function. Furthermore, it may require specific stimulation for activation. In 
vitro, there is evidence that it exists in the active, inducible and inactive 
states. Active CD44 constitutively binds hyaluronan, while inducible CD44 
bind hyaluronan weakly or not at all, unless stimulated; and inactive CD44 
does not bind hyaluronan even in the presence of inducing factors.77 All 
these permutations, and the high likelihood that each CD44 isoform has its 
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independent function, contribute to the complexities in clearly elucidating 
the role of CD44 because meaningful comparisons between different 
series that use differing isoforms is not possible.   
 
In this work, the association between the IHC expression of the standard 
isoform of CD44, CD44s, and clinical outcomes was explored. It might well 
be that CD44s is not the splice variant that most appropriately reflects 
CD44 role as a stem cell marker and the actual function of CD44s in oral 
tongue SCC in our experiments is still unknown. 
 
The use of IHC to quantify CD44s expression may also not be most ideal 
method to explore its role as a cancer stem cell marker. In research 
demonstrating CD44 as a cell surface marker for cancer stem cells, flow 
cytometry analysis is often used to quantify the proportion of tumour 
epithelial cells expressing the molecule. FACS is quantitative for the given 
volume of tumour, and excludes stromal and inflammatory cells that may 
express CD44. Furthermore, a pan-CD44 antibody, instead of quantifying 
a specific variant is used. In contrast, IHC is a semi-quantitative evaluation 
based on an individual observer’s estimate of CD44 expression on a 
histological section that may have limited ability to represent the entire 
tumour. It is also difficult on IHC staining to quantitatively differentiate 
between staining of tumour and non-tumour cells. Yet, despite recognizing 
the limitations of IHC, the reason why we, and many other studies, 
explored the use of IHC to quantify CD44 expression is because it is the 
method of quantifying most likely to be of clinical relevance. However, 
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differences in the methods of categorizing the immunoexpression of CD44 
also exist and add further to the difficulty of evaluating the existing 
literature. Determined arbitrarily by individual investigators, some looked at 
the regularity of staining patterns, others the percentage of cells that stain, 
and yet others that quantify the staining intensity – all with differing 
categories. Such differences effectively preclude meaningful comparisons 
between published studies. Perhaps studies to examine if FACS and IHC 
give comparable findings should be done, as should the best way to 
quantify immunoexpression be identified.  
 
Certainly the standardization of techniques and approaches to analyse the 
heterogenous CD44 molecule on human cancers across laboratories 
worldwide may help obtain more consistent data from patient specimens. 
With regards to head and neck cancers, evaluation based on individual 
subsites is also likely to distil further, relevant results. Too often, entire 
cohorts of head and neck cancers without a subsite focus are analysed, 
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4.3 Directions for future research  
 
As basic science research delves further to clarify the function of the CD44 
protein in head and neck cancers, there are perhaps 3 main applications in 
the arena of clinical investigation in which CD44 and its isoforms may 
prove useful. The first, as we explored with CD44s in oral tongue cancer, 
is its role as a prognostic marker. Refinement of the choice of technique 
employed to measure expression and identifying the most indicative splice 
variant has potential to greatly aid prognosis.  
 
The second potential area of clinical application is as a marker of 
radioresistance and/or chemoresistance and hence a predictor to 
treatment failures. The underlying concept to this is the cancer stem cell 
hypothesis. Cancer stem cells of breast cancer cell lines and glioblastoma 
stem cells in vivo have been shown to be radioresistant. In glioblastoma, 
these cells accumulated after radiation therapy, and by examining known 
molecular markers of radiation damage, it was concluded that the group of 
cancer initiating cells defined by CD133+ expression could repair DNA 
damage more efficiently and hence survive. Perhaps more interesting was 
the ability to radiosensitize CD133+ cells by inhibiting DNA damage check 
point kinases Chk1 and Chk2. Should CD44 as a cancer stem cell marker 
in head and neck cancer have similar ability, the potential clinical 
implications are significant. Potentially we may identify the patients at risk 
of failure with radiotherapy and pre-emptively select a different treatment 
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modality or, should we be able to target and effect radiosensitization, do 
so prior to treatment. A similar trend of clinical application exists for head 
and neck cancer with chemotherapy where CD44 – hyaluronan signaling 
has been shown to play a role in cisplatin resistance. We had hoped to 
investigate this aspect by determining if CD44s expression had a 
correlation with success of treatment with upfront concurrent 
chemoradiotherapy. Our initial dataset of patients with locally advanced 
head and neck cancers treated primary chemoradiotherapy might have 
shed light on a possible association with treatment failure. Unfortunately 
we failed to optimize a suitable IHC protocol for the archived specimens 
from 1996 – 2002 and we were compelled to change our experimental 
plan and forsake this aspect. 
 
The third clinical area of great potential is the use of CD44 as a target for 
therapy. As a cell surface antigen, its expression is perhaps not sufficiently 
specific to allow for precise targeting. This is due to its ubiquitous 
expression on a large variety of cells. This is illustrated in the phase I 
study reported by Riechelmann et al., that investigated the use of the 
antimitotic agent, mertansine, conjugated with the monoclonal antibody, 
bivatsuzumab, specific for CD44v6. The potent derivative, bivatuzumab 
mertansine, was used as a selective cytotoxic agent to target CD44v6 
expressed by HNSCC in patients with recurrent or metastatic disease. 
Although effective, the side effects were significant due largely to the fact 
that CD44v6 is also expressed on dermal keratinocytes, and the trial 
reported one death from toxic epidermal necrolyis.  Its use as a 
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therapeutic agent has since been curtailed. Nonetheless, this highlights 
the potential of CD44, and perhaps its more cancer-specific associated 
signaling pathways, as potential therapeutic targets for novel therapies.  
 
 
4.4 CONCLUSION   
 
This study examined the clinical implications of CD44s expression in a 
population of oral tongue SCC. It was based on the hypothesis that CD44, 
a putative cancer stem cell marker of head and neck SCC, may have 
prognostic significance in the clinical outcomes of patients with oral tongue 
SCC, be a potential biomarker for increased resistance to chemotherapy 
and radiotherapy, and may be associated with adverse histopathological 
features. We found instead, that CD44s is abundantly expressed in oral 
tongue SCC, and when strongly expressed, is a good prognostic marker 
for both overall survival and locoregional recurrence-free interval. 
Immunoexpression of CD44s is therefore unlikely to itself reflect the 
proportion of cancer stem cells within oral tongue SCC.  
 
More coordinated research is needed to definitively define the role of 
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